Author: globestrategy

Over the last decade the pharmaceutical industry has seen many of its blockbuster products come off patent in therapy areas such as cardiovascular, diabetes and respiratory. <ClickHere> 

With some of the world’s best-known biologics continuing to face patent expiration in the coming years, the biosimilars market is set for continued growth. <ClickHere>

According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. <ClickHere>

The coronavirus outbreak is bringing attention to the fast-growing vaccine industry. The vaccine market has grown sixfold over the past two decades, worth more than $35 billion today, according to AB Bernstein. <ClickHere> 

Sanofi is now back to the market’s attention mainly because of its efforts in tackling the Covid-19 pandemic. <ClickHere> 

Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned. <ClickHere> 

There is a groundswell in Africa in support of local pharmaceutical production. Africa’s dependency on the rest of the world for medicines may not last long. <ClickHere> 

Multinationals (MNCs) were thrilled by China’s recent policies on opening up the domestic pharmaceutical market to the world. <ClickHere> 

The pharmaceutical industry is characterized by high R&D costs and increasing competition. New pharmaceutical products are often provided patent protection to help companies recoup their R&D costs. <ClickHere>